+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Metabolic Disorders Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030

  • ID: 5292713
  • Report
  • February 2021
  • Region: Global
  • 300 pages
  • The Business Research Company
1 of 5

FEATURED COMPANIES

  • AstraZeneca Plc
  • Johnson & Johnson
  • Merck & Co
  • Novo Nordisk A/S
  • Sanofi S.A
  • MORE
Metabolic Disorders Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030 provides the strategists, marketers and senior management with the critical information they need to assess the global metabolic disorders drugs market as it emerges from the COVID-19 shut down.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Description:

Where is the largest and fastest growing market for the metabolic disorders drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Metabolic Disorders Drugs market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider metabolic disorders drugs market, and compares it with other markets.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the impact of the COVID-19 virus and forecasting its recovery.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
  • The metabolic disorders drugs market section of the report gives context. It compares the metabolic disorders drugs market with other segments of the pharmaceutical drugs market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, metabolic disorders drugs indicators comparison.
Scope

Markets Covered:
1) By Type: Anti Diabetics drugs; Anti-Thyroid Drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies/Drug Stores; Others
3) By Route Of Administration: Oral; Parenteral; Others
4) By Drug Classification: Branded Drugs; Generic Drugs
5) By Mode Of Purchase: Prescription-Based Drugs; Over-The-Counter Drugs

Companies Mentioned: Sanofi S.A; Novo Nordisk A/S; AstraZeneca Plc; Johnson & Johnson; Merck & Co

Metrics Covered: Number of Enterprises; Number of Employees

Countries: Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; China; Colombia; Czech Republic; Denmark; Egypt; Finland; France; Germany; Hong Kong; India; Indonesia; Ireland; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; New Zealand; Nigeria; Norway; Peru; Philippines; Poland; Portugal; Romania; Russia; Saudi Arabia; Singapore; South Africa; South Korea; Spain; Sweden; Switzerland; Thailand; Turkey; UAE; UK; USA; Venezuela; Vietnam

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita, metabolic disorders drugs indicators comparison.

Data segmentations: Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

This report will be delivered within 1-3 business days.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AstraZeneca Plc
  • Johnson & Johnson
  • Merck & Co
  • Novo Nordisk A/S
  • Sanofi S.A
  • MORE
1. Executive Summary

2. Report Structure

3. Metabolic Disorders Drugs Market Characteristics
3.1. Market Definition
3.2. Key Segmentations

4. Metabolic Disorders Drugs Market Product Analysis
4.1. Leading Products/ Services
4.2. Key Features and Differentiators
4.3. Development Products

5. Metabolic Disorders Drugs Market Supply Chain
5.1. Supply Chain
5.2. Distribution
5.3. End Customers

6. Metabolic Disorders Drugs Market Customer Information
6.1. Customer Preferences
6.2. End Use Market Size and Growth

7. Metabolic Disorders Drugs Market Trends and Strategies

8. Impact of COVID-19 on Metabolic Disorders Drugs

9. Metabolic Disorders Drugs Market Size and Growth
9.1. Market Size
9.2. Historic Market Growth, Value ($ Billion)
9.2.1. Drivers of the Market
9.2.2. Restraints on the Market
9.3. Forecast Market Growth, Value ($ Billion)
9.3.1. Drivers of the Market
9.3.2. Restraints on the Market

10. Metabolic Disorders Drugs Market Regional Analysis
10.1. Global Metabolic Disorders Drugs Market, 2020, by Region, Value ($ Billion)
10.2. Global Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Region
10.3. Global Metabolic Disorders Drugs Market, Growth and Market Share Comparison, by Region

11. Metabolic Disorders Drugs Market Segmentation
11.1. Global Metabolic Disorders Drugs Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Anti Diabetics drugs
  • Anti-Thyroid Drugs
  • Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)
11.2. Global Metabolic Disorders Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies/ Drug Stores
  • Others
11.3. Global Metabolic Disorders Drugs Market, Segmentation by Route of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Oral
  • Parenteral
  • Others
11.4. Global Metabolic Disorders Drugs Market, Segmentation by Drug Classification, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Branded Drugs
  • Generic Drugs
11.5. Global Metabolic Disorders Drugs Market, Segmentation by Mode of Purchase, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Prescription-Based Drugs
  • Over-The-Counter Drugs
12. Metabolic Disorders Drugs Market Metrics
12.1. Metabolic Disorders Drugs Market Size, Percentage of GDP, 2015-2025, Global
12.2. Per Capita Average Metabolic Disorders Drugs Market Expenditure, 2015-2025, Global

13. Asia-Pacific Metabolic Disorders Drugs Market
13.1. Asia-Pacific Metabolic Disorders Drugs Market Overview
  • Region Information, Impact of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
13.2. Asia-Pacific, Metabolic Disorders Drugs Market, 2020, by Country, Value ($ Billion)
13.3. Asia-Pacific, Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
13.4. Asia-Pacific, Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
13.5. Asia-Pacific, Metabolic Disorders Drugs Market Metrics
13.5.1. Per Capita Average Metabolic Disorders Drugs Expenditure, 2015-2025, Asia-Pacific Countries
13.6. Asia-Pacific Metabolic Disorders Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7. Asia-Pacific Metabolic Disorders Drugs Market: Country Analysis
13.7.1. China Metabolic Disorders Drugs Market
13.7.1.1. China Metabolic Disorders Drugs Market Overview
13.7.1.2. China Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.1.3. China Metabolic Disorders Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.2. Australia Metabolic Disorders Drugs Market
13.7.2.1. Australia Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.2.2. Australia Metabolic Disorders Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.3. Hong Kong Metabolic Disorders Drugs Market
13.7.3.1. Hong Kong Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.4. India Metabolic Disorders Drugs Market
13.7.4.1. India Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.4.2. India Metabolic Disorders Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.5. Indonesia Metabolic Disorders Drugs Market
13.7.5.1. Indonesia Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.5.2. Indonesia Metabolic Disorders Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.6. Japan Metabolic Disorders Drugs Market
13.7.6.1. Japan Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.6.2. Japan Metabolic Disorders Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.7. Malaysia Metabolic Disorders Drugs Market
13.7.7.1. Malaysia Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.8. New Zealand Metabolic Disorders Drugs Market
13.7.8.1. New Zealand Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.9. Philippines Metabolic Disorders Drugs Market
13.7.9.1. Philippines Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.10. Singapore Metabolic Disorders Drugs Market
13.7.10.1. Singapore Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.11. South Korea Metabolic Disorders Drugs Market
13.7.11.1. South Korea Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.11.2. South Korea Metabolic Disorders Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.12. Thailand Metabolic Disorders Drugs Market
13.7.12.1. Thailand Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.13. Vietnam Metabolic Disorders Drugs Market
13.7.13.1. Vietnam Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)

14. Western Europe Metabolic Disorders Drugs Market
14.1. Western Europe Metabolic Disorders Drugs Market Overview
14.2. Western Europe, Metabolic Disorders Drugs Market, 2020, by Country, Value ($ Billion)
14.3. Western Europe, Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
14.4. Western Europe, Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
14.5. Western Europe, Metabolic Disorders Drugs Market Metrics
14.5.1. Per Capita Average Metabolic Disorders Drugs Expenditure, 2015-2025, Western Europe Countries
14.6. Western Europe Metabolic Disorders Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7. Western Europe Metabolic Disorders Drugs Market: Country Analysis
14.7.1. Austria Metabolic Disorders Drugs Market
14.7.1.1. Austria Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.2. Belgium Metabolic Disorders Drugs Market
14.7.2.1. Belgium Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.3. Denmark Metabolic Disorders Drugs Market
14.7.3.1. Denmark Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.4. Finland Metabolic Disorders Drugs Market
14.7.4.1. Finland Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.5. France Metabolic Disorders Drugs Market
14.7.5.1. France Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.5.2. France Metabolic Disorders Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.6. Germany Metabolic Disorders Drugs Market
14.7.6.1. Germany Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.6.2. Germany Metabolic Disorders Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.7. Ireland Metabolic Disorders Drugs Market
14.7.7.1. Ireland Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.8. Italy Metabolic Disorders Drugs Market
14.7.8.1. Italy Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.9. Netherlands Metabolic Disorders Drugs Market
14.7.9.1. Netherlands Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.10. Norway Metabolic Disorders Drugs Market
14.7.10.1. Norway Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.11. Portugal Metabolic Disorders Drugs Market
14.7.11.1. Portugal Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.12. Spain Metabolic Disorders Drugs Market
14.7.12.1. Spain Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.13. Sweden Metabolic Disorders Drugs Market
14.7.13.1. Sweden Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.14. Switzerland Metabolic Disorders Drugs Market
14.7.14.1. Switzerland Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.15. UK Metabolic Disorders Drugs Market
14.7.15.1. UK Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.15.2. UK Metabolic Disorders Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)

15. Eastern Europe Metabolic Disorders Drugs Market
15.1. Eastern Europe Metabolic Disorders Drugs Market Overview
15.2. Eastern Europe, Metabolic Disorders Drugs Market, 2020, by Country, Value ($ Billion)
15.3. Eastern Europe, Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
15.4. Eastern Europe, Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
15.5. Eastern Europe, Metabolic Disorders Drugs Market Metrics
15.5.1. Per Capita Average Metabolic Disorders Drugs Expenditure, 2015-2025, Eastern Europe Countries
15.6. Eastern Europe Metabolic Disorders Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7. Eastern Europe Metabolic Disorders Drugs Market: Country Analysis
15.7.1. Czech Republic Metabolic Disorders Drugs Market,
15.7.1.1. Czech Republic Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.2. Poland Metabolic Disorders Drugs Market
15.7.2.1. Poland Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.3. Romania Metabolic Disorders Drugs Market
15.7.3.1. Romania Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.4. Russia Metabolic Disorders Drugs Market
15.7.4.1. Russia Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.4.2. Russia Metabolic Disorders Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)

16. North America Metabolic Disorders Drugs Market
16.1. North America Metabolic Disorders Drugs Market Overview
16.2. North America, Metabolic Disorders Drugs Market, 2020, by Country, Value ($ Billion)
16.3. North America, Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
16.4. North America, Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
16.5. North America, Metabolic Disorders Drugs Market Metrics
16.5.1. Per Capita Average Metabolic Disorders Drugs Expenditure, 2015-2025, North America Countries
16.6. North America Metabolic Disorders Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
16.7. North America Metabolic Disorders Drugs Market: Country Analysis
16.7.1. Canada Metabolic Disorders Drugs Market
16.7.1.1. Canada Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
16.7.2. Mexico Metabolic Disorders Drugs Market
16.7.2.1. Mexico Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
16.7.3. USA Metabolic Disorders Drugs Market
16.7.3.1. USA Metabolic Disorders Drugs Market Overview
16.7.3.2. USA Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
16.7.3.3. USA Metabolic Disorders Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)

17. South America Metabolic Disorders Drugs Market
17.1. South America Metabolic Disorders Drugs Market Overview
17.2. South America, Metabolic Disorders Drugs Market, 2020, by Country, Value ($ Billion)
17.3. South America, Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
17.4. South America, Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
17.5. South America, Metabolic Disorders Drugs Market Metrics
17.5.1. Per Capita Average Metabolic Disorders Drugs Expenditure, 2015-2025, South America Countries
17.6. South America Metabolic Disorders Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7. South America Metabolic Disorders Drugs Market: Country Analysis
17.7.1. Argentina Metabolic Disorders Drugs Market
17.7.1.1. Argentina Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7.2. Brazil Metabolic Disorders Drugs Market
17.7.1.1. Brazil Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7.2.2. Brazil Metabolic Disorders Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7.3. Chile Metabolic Disorders Drugs Market
17.7.3.1. Chile Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7.4. Colombia Metabolic Disorders Drugs Market
17.7.4.1. Colombia Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7.5. Peru Metabolic Disorders Drugs Market
17.7.5.1. Peru Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7.6. Venezuela Metabolic Disorders Drugs Market
17.7.6.1. Venezuela Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)

18. Middle East Metabolic Disorders Drugs Market
18.1. Middle East Metabolic Disorders Drugs Market Overview
18.2. Middle East, Metabolic Disorders Drugs Market, 2020, by Country, Value ($ Billion)
18.3. Middle East, Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
18.4. Middle East, Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
18.5. Middle East, Metabolic Disorders Drugs Market Metrics
18.5.1. Per Capita Average Metabolic Disorders Drugs Expenditure, 2015-2025, Middle East Countries
18.6. Middle East Metabolic Disorders Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
18.7. Middle East Metabolic Disorders Drugs Market: Country Analysis
18.7.1. Saudi Arabia Metabolic Disorders Drugs Market
18.7.1.1. Saudi Arabia Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
18.7.2. Israel Metabolic Disorders Drugs Market
18.7.2.1. Israel Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
18.7.3. Turkey Metabolic Disorders Drugs Market
18.7.3.1. Turkey Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
18.7.4. UAE Metabolic Disorders Drugs Market
18.7.4.1. UAE Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)

19. Africa Metabolic Disorders Drugs Market
19.1. Africa Metabolic Disorders Drugs Market Overview
19.2. Africa, Metabolic Disorders Drugs Market, 2020, by Country, Value ($ Billion)
19.3. Africa, Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
19.4. Africa, Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
19.5. Africa, Metabolic Disorders Drugs Market Metrics
19.5.1. Per Capita Average Metabolic Disorders Drugs Expenditure, 2015-2025, Africa Countries
19.6. Africa Metabolic Disorders Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
19.7. Africa Metabolic Disorders Drugs Market: Country Analysis
19.7.1. Egypt Metabolic Disorders Drugs Market
19.7.1.1. Egypt Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
19.7.2. Nigeria Metabolic Disorders Drugs Market
19.7.2.1. Nigeria Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
19.7.3. South Africa Metabolic Disorders Drugs Market
19.7.3.1. South Africa Metabolic Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)

20. Metabolic Disorders Drugs Market Competitive Landscape
20.1. Competitive Market Overview
20.2. Market Shares
20.3. Company Profiles
20.3.1. Sanofi S.A
20.3.1.1. Company Overview
20.3.1.2. Products and Services
20.3.1.3. Strategy
20.3.1.4. Financial Performance
20.3.2. Novo Nordisk A/S
20.3.2.1. Company Overview
20.3.2.2. Products and Services
20.3.2.3. Strategy
20.3.2.4. Financial Performance
20.3.3. AstraZeneca Plc
20.3.3.1. Company Overview
20.3.3.2. Products and Services
20.3.3.3. Strategy
20.3.3.4. Financial Performance
20.3.4. Johnson & Johnson
20.3.4.1. Company Overview
20.3.4.2. Products and Services
20.3.4.3. Strategy
20.3.4.4. Financial Performance
20.3.5. Merck & Co
20.3.5.1. Company Overview
20.3.5.2. Products and Services
20.3.5.3. Strategy
20.3.5.4. Financial Performance

21. Key Mergers and Acquisitions in the Metabolic Disorders Drugs Market

22. Market Background: Pharmaceutical Drugs Market
22.1. Pharmaceutical Drugs Market Characteristics
22.2. Pharmaceutical Drugs Market Historic and Forecast, 2015-2020, 2020-2025F, 2030F Growth, by Segment, Value ($ Billion), Global
22.3. Global Pharmaceutical Drugs Market, 2020, by Region, Value ($ Billion)
22.4. Global Pharmaceutical Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Region
22.5. Global Pharmaceutical Drugs Market, 2015-2020, 2020-2025F, 2030F, Segmentation by Type, Value ($ Billion)

23. Recommendations
23.1. Global Metabolic Disorders Drugs Market in 2025 - Growth Countries
23.2. Global Metabolic Disorders Drugs Market in 2025 - Growth Segments
23.3. Global Metabolic Disorders Drugs Market in 2025 - Growth Strategies

24. Appendix
24.1. NAICS Definitions of Industry Covered in This Report
24.2. Abbreviations
24.3. Currencies
24.4. Research Inquiries
24.5. About the Publisher

25. Copyright and Disclaimer
Note: Product cover images may vary from those shown
3 of 5

FEATURED COMPANIES

  • AstraZeneca Plc
  • Johnson & Johnson
  • Merck & Co
  • Novo Nordisk A/S
  • Sanofi S.A
  • MORE
Major companies in the metabolic disorders drugs market include Sanofi S.A; Novo Nordisk A/S; AstraZeneca Plc; Johnson & Johnson and Merck & Co.

The global metabolic disorders drugs market is expected to grow from $143.16 billion in 2020 to $146.25 billion in 2021 at a compound annual growth rate (CAGR) of 2.2%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $198.07 billion in 2025 at a CAGR of 8%.

The metabolic disorders drugs market consists of sales of metabolic disorders drugs and related services by entities (organizations, sole traders and partnerships) that produce metabolic disorders drugs to treat metabolic diseases. This industry includes establishments that produce drugs such as insulin, pramlintide and other drugs to treat diabetes, anti-thyroid drugs to treat hyperthyroidism, and other drugs to treat pituitary gland, adrenal gland and parathyroid gland disorders. The metabolic disorders drugs market is segmented into anti diabetic drugs; anti-thyroid drugs; and others (hyperparathyroidism, hypopituitarism, hypoadrenalism).

North America was the largest region in the global metabolic disorders drugs market, accounting for 54% of the market in 2020. Asia Pacific was the second largest region accounting for 24% of the global metabolic disorders drugs market. Africa was the smallest region in the global metabolic disorders drugs market.

Companies are focusing on employing artificial intelligence applications to revolutionize the treatment of metabolic disorders. Artificial Intelligence is a machine-based learning which makes use of human intelligence functionalities like reasoning and problem-solving abilities to obtain insights and provide useful information. This technology radically changes the treatment of metabolic syndrome by analyzing large sets of chemical and biological data to identify potential drug candidates with higher success rates and at a quicker pace when compared to human analysis. 3BIGS, a Korean biodata analysis-based company that studies the relation between diseases, targets and drugs is using AI technology to help researches repurpose the drugs for additional diseases.

Regulatory agencies and federal governments adopted stringent regulations and took a tough stance on drug pricing by pharmaceutical companies during the historic period. Pharmaceutical companies faced criticism from politicians, patients and physicians over high pricing of some medicines and drugs. Moreover, companies had to sell drugs and medicines at subsidized rates to government hospitals, doctors and clinics, further effecting companies’ revenues. This led to drug manufacturing companies operating on a reduced profit margin, which negatively impacted the attractiveness of the metabolic disorders drugs industry in the historic period.

The rise in sedentary jobs, busy lifestyles and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as diabetes and obesity. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of metabolic disorders. According to the World Health Organization, chronic disease prevalence is expected to rise by 57% globally, by the year 2020. These factors are expected to increase the patient pool globally, thereby driving the metabolic disorders drugs market during the forecast period.
Note: Product cover images may vary from those shown
4 of 5
  • Sanofi S.A
  • Novo Nordisk A/S
  • AstraZeneca Plc
  • Johnson & Johnson
  • Merck & Co
Note: Product cover images may vary from those shown
5 of 5

Loading
LOADING...

Adroll
adroll